Ocular Therapeutix (OCUL) Initiated At Oppenheimer And RBC Capital Markets

Analysts at Oppenheimer initiated coverage on Ocular Therapeutix (OCUL) with a ‘Outperform’ rating and a $25 price target in a research report issued to clients on Tuesday. The firm sees the company as an appealing platform play in the ophthalmology space, and believes that at current levels even a conservative view of peak share suggests significant upside. Ocular shares were also initiated this morning with a ‘Outperform’ rating and a $21 price target at RBC Capital Markets.

Shares of Ocular Therapeutix traded as high as $14.41 Monday, before ending the day at $14.02. In the past 52 weeks, OCUL has traded between a low of $11.90 and a high of $15.25, which is more than 28% above that low price. Over the past week alone the stock has gained 7.50%. Ticker is up 8.97% on a year-over-year basis.

The chart below shows where the stock has traded over the last year, with the 50-day and 200-day moving averages included.

Ocular Therapeutix, Inc is a development stage biopharmaceutical company, focused on the development and commercialization of ophthalmic therapeutic products. The firm was founded in 2006 and is headquartered in Bedford, Massachusetts.

Create Content With AI

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.